Commercial Post-marketing oncology studies: Enabling faster recruitment and lower costs pharminent June 22, 2026
Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
M&A / Deals GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year pharminent June 9, 2026
M&A / Deals J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B pharminent June 8, 2026
Pipeline Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? pharminent June 5, 2026
M&A / Deals Regeneron deepens relationship with CytomX, adding up to $2B and eight targets pharminent June 4, 2026
Manufacturing Cellares and TScan to assess automated manufacturing of TSC-101 therapy pharminent June 4, 2026
Clinical Data ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come pharminent June 2, 2026
Clinical Data ASCO: Merck overshadowed by upstart biotechs but TROP2 plans begin to pay off pharminent June 2, 2026
Other ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer pharminent June 2, 2026
Clinical Data ASCO: Summit reached with China lung data but new climb begins to prove global benefit pharminent June 1, 2026
Regulatory FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy pharminent June 1, 2026
Clinical Data Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers pharminent May 29, 2026
Regulatory Replimune gives cancer immunotherapy a third try after FDA leadership shakeup pharminent May 29, 2026
M&A / Deals Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent pharminent May 29, 2026
Clinical Data Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival pharminent May 22, 2026
Clinical Data Merck ADC, licensed from China, hits mark in first big global trial pharminent May 18, 2026
Other Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studies pharminent May 18, 2026
Regulatory FDA approves Enhertu for two HER2-positive early breast cancer indications pharminent May 18, 2026
